iBio, Inc. is a biopharmaceutical company focused on the development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases. It has a pipeline of proprietary products in preclinical development, including sub-unit vaccines directed against both seasonal and pandemic influenza, sub-unit vaccines for prevention of anthrax and plague, sub-unit vaccines for treatment of HPV infections, therapeutic antibodies for treatment of anthrax and antibodies for prevention, treatment and diagnosis of pandemic influenza